Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intellia Therapeutics, Inc. (NTLA) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Intellia Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1652130.
Total stock buying since 2016: $24,121,110.
Total stock sales since 2016: $310,969,401.
Total stock option exercises since 2016: $20,790,694.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 100,000 | $1,002,999 | 78,140 | $936,927 | 0 | $0 |
| 2024 | 0 | $0 | 54,450 | $1,574,229 | 0 | $0 |
| 2023 | 0 | $0 | 7,757 | $330,506 | 57,791 | $61,350 |
| 2022 | 0 | $0 | 5,705 | $640,377 | 17,597 | $0 |
| 2021 | 0 | $0 | 2,378,232 | $239,032,298 | 1,145,355 | $16,539,086 |
| 2020 | 0 | $0 | 315,835 | $11,613,897 | 375,633 | $4,082,418 |
| 2019 | 7,500 | $118,125 | 0 | $0 | 0 | $0 |
| 2018 | 0 | $0 | 618,348 | $16,471,941 | 8,000 | $107,840 |
| 2017 | 0 | $0 | 3,250,893 | $40,369,226 | 0 | $0 |
| 2016 | 1,277,777 | $22,999,986 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 100,000 | $1,002,999 | 0 | $0 | 0 | $0 |
| 2025-07 | 0 | $0 | 12,534 | $153,835 | 0 | $0 |
| 2025-06 | 0 | $0 | 1,547 | $14,789 | 0 | $0 |
| 2025-04 | 0 | $0 | 265 | $2,252 | 0 | $0 |
| 2025-03 | 0 | $0 | 3,251 | $29,226 | 0 | $0 |
| 2025-01 | 0 | $0 | 60,543 | $736,825 | 0 | $0 |
| 2024-10 | 0 | $0 | 2,012 | $38,248 | 0 | $0 |
| 2024-07 | 0 | $0 | 405 | $9,286 | 0 | $0 |
| 2024-06 | 0 | $0 | 1,505 | $37,625 | 0 | $0 |
| 2024-01 | 0 | $0 | 50,528 | $1,489,070 | 0 | $0 |
| 2023-10 | 0 | $0 | 265 | $6,333 | 0 | $0 |
| 2023-07 | 0 | $0 | 2,492 | $99,173 | 0 | $0 |
| 2023-06 | 0 | $0 | 5,000 | $225,000 | 5,000 | $61,350 |
| 2023-01 | 0 | $0 | 0 | $0 | 52,791 | $0 |
| 2022-01 | 0 | $0 | 5,705 | $640,377 | 17,597 | $0 |
| 2021-11 | 0 | $0 | 2,400 | $320,244 | 2,400 | $30,287 |
| 2021-10 | 0 | $0 | 14,900 | $1,916,434 | 14,900 | $265,660 |
| 2021-09 | 0 | $0 | 50,617 | $8,591,671 | 58,540 | $1,115,108 |
| 2021-08 | 0 | $0 | 304,258 | $46,926,592 | 304,258 | $4,417,415 |
| 2021-06 | 0 | $0 | 755,101 | $92,501,178 | 0 | $0 |
| 2021-04 | 0 | $0 | 444,439 | $37,971,817 | 201,479 | $2,609,962 |
| 2021-02 | 0 | $0 | 796,823 | $50,262,856 | 543,778 | $7,825,054 |
| 2021-01 | 0 | $0 | 9,694 | $541,506 | 20,000 | $275,600 |
| 2020-12 | 0 | $0 | 92,128 | $4,879,742 | 119,223 | $1,734,239 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-20 | Chase William J | Buy | 100,000 | 10.03 | 1,002,999 |
| 2025-07-23 | Dulac Edward J Iii (EVP, Chief Financial Officer) | Sale | 7,462 | 14.02 | 104,617 |
| 2025-07-02 | Dube Michael P (VP, Chief Accounting Officer) | Sale | 2,503 | 9.95 | 24,904 |
| 2025-07-01 | Clark Eliana (EVP, Chief Technical Officer) | Sale | 1,022 | 9.82 | 10,036 |
| 2025-07-01 | Goodman Jesse | Sale | 1,547 | 9.23 | 14,278 |
| 2025-06-30 | Goodman Jesse | Sale | 1,547 | 9.56 | 14,789 |
| 2025-04-29 | Bhanji Muna | Sale | 265 | 8.50 | 2,252 |
| 2025-03-04 | Clark Eliana (EVP, Chief Technical Officer) | Sale | 679 | 8.99 | 6,104 |
| 2025-03-04 | Basta James (EVP, General Counsel) | Sale | 2,572 | 8.99 | 23,122 |
| 2025-01-29 | Bhanji Muna | Sale | 265 | 9.97 | 2,642 |
| 2025-01-03 | Dube Michael P (VP, Chief Accounting Officer) | Sale | 1,372 | 12.18 | 16,710 |
| 2025-01-03 | Hicks Derek (EVP, Chief Business Officer) | Sale | 6,502 | 12.18 | 79,194 |
| 2025-01-03 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 9,557 | 12.18 | 116,404 |
| 2025-01-03 | Basta James (EVP, General Counsel) | Sale | 7,074 | 12.18 | 86,161 |
| 2025-01-03 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Sale | 8,966 | 12.18 | 109,205 |
| 2025-01-03 | Leonard John M (President and CEO) | Sale | 26,807 | 12.18 | 326,509 |
| 2024-10-02 | Dube Michael P (VP, Chief Accounting Officer) | Sale | 2,012 | 19.01 | 38,248 |
| 2024-07-01 | Clark Eliana (EVP, Chief Technical Officer) | Sale | 405 | 22.93 | 9,286 |
| 2024-06-17 | Verwiel Frank | Sale | 1,505 | 25.00 | 37,625 |
| 2024-01-08 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Sale | 2,275 | 29.02 | 66,020 |
| 2024-01-03 | Clark Eliana (EVP, Chief Technical Officer) | Sale | 4,608 | 29.79 | 137,272 |
| 2024-01-03 | Hicks Derek (EVP, Chief Business Officer) | Sale | 3,877 | 29.46 | 114,216 |
| 2024-01-03 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 5,843 | 29.46 | 172,134 |
| 2024-01-03 | Basta James (EVP, General Counsel) | Sale | 3,805 | 29.46 | 112,095 |
| 2024-01-03 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Sale | 5,532 | 29.46 | 162,972 |
| 2024-01-03 | Goddard Glenn (EVP, Chief Financial Officer) | Sale | 5,365 | 29.46 | 158,052 |
| 2024-01-03 | Leonard John M (President and CEO) | Sale | 19,223 | 29.46 | 566,309 |
| 2023-10-31 | Bhanji Muna (Director) | Sale | 265 | 23.90 | 6,333 |
| 2023-07-31 | Bhanji Muna (Director) | Sale | 265 | 42.33 | 11,217 |
| 2023-07-06 | Bhanji Muna (Director) | Sale | 1,867 | 39.30 | 73,373 |
| 2023-07-03 | Clark Eliana (EVP, Chief Technical Officer) | Sale | 360 | 40.51 | 14,583 |
| 2023-06-20 | Clark Eliana (EVP, Chief Technical Officer) | Sale | 5,000 | 45.00 | 225,000 |
| 2023-06-20 | Clark Eliana (EVP, Chief Technical Officer) | Option Ex | 5,000 | 12.27 | 61,350 |
| 2023-01-01 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 6,374 | .00 | 0 |
| 2023-01-01 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Option Ex | 7,000 | .00 | 0 |
| 2023-01-01 | Goddard Glenn (EVP, Chief Financial Officer) | Option Ex | 6,124 | .00 | 0 |
| 2023-01-01 | Leonard John M (President and CEO) | Option Ex | 15,696 | .00 | 0 |
| 2022-01-01 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 1,051 | 112.24 | 117,964 |
| 2022-01-01 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 3,187 | .00 | 0 |
| 2022-01-01 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Sale | 1,148 | 112.25 | 128,863 |
| 2022-01-01 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Option Ex | 3,500 | .00 | 0 |
| 2022-01-01 | Goddard Glenn (EVP, Chief Financial Officer) | Sale | 1,013 | 112.24 | 113,699 |
| 2022-01-01 | Goddard Glenn (EVP, Chief Financial Officer) | Option Ex | 3,062 | .00 | 0 |
| 2022-01-01 | Leonard John M (President and CEO) | Sale | 2,493 | 112.25 | 279,851 |
| 2022-01-01 | Leonard John M (President and CEO) | Option Ex | 7,848 | .00 | 0 |
| 2021-11-05 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 2,400 | 133.44 | 320,244 |
| 2021-11-05 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-10-14 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 2,400 | 128.81 | 309,139 |
| 2021-10-14 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-10-11 | Crowley John F (Director) | Sale | 2,500 | 119.55 | 298,875 |
| 2021-10-11 | Crowley John F (Director) | Option Ex | 2,500 | 18.83 | 47,074 |
| 2021-10-05 | Crowley John F (Director) | Sale | 10,000 | 130.84 | 1,308,420 |
| 2021-10-05 | Crowley John F (Director) | Option Ex | 10,000 | 18.83 | 188,299 |
| 2021-09-24 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 7,923 | 12.62 | 99,988 |
| 2021-09-21 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 2,400 | 149.81 | 359,544 |
| 2021-09-21 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-09-07 | Goddard Glenn (EVP, Chief Financial Officer) | Sale | 3,482 | 180.12 | 627,177 |
| 2021-09-07 | Goddard Glenn (EVP, Chief Financial Officer) | Option Ex | 3,482 | 14.58 | 50,767 |
| 2021-09-01 | Leonard John M (President and CEO) | Sale | 44,735 | 170.00 | 7,604,950 |
| 2021-09-01 | Leonard John M (President and CEO) | Option Ex | 44,735 | 20.88 | 934,066 |
| 2021-08-31 | Goddard Glenn (EVP, Chief Financial Officer) | Sale | 24,800 | 160.22 | 3,973,456 |
| 2021-08-31 | Goddard Glenn (EVP, Chief Financial Officer) | Option Ex | 24,800 | 16.93 | 419,740 |
| 2021-08-31 | Leonard John M (President and CEO) | Sale | 37,833 | 155.00 | 5,864,115 |
| 2021-08-31 | Leonard John M (President and CEO) | Option Ex | 37,833 | 14.58 | 551,605 |
| 2021-08-30 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 2,400 | 157.80 | 378,729 |
| 2021-08-30 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-08-30 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Sale | 97,000 | 156.70 | 15,200,288 |
| 2021-08-30 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Option Ex | 97,000 | 13.82 | 1,341,025 |
| 2021-08-30 | Goddard Glenn (EVP, Chief Financial Officer) | Sale | 5,200 | 156.88 | 815,765 |
| 2021-08-30 | Goddard Glenn (EVP, Chief Financial Officer) | Option Ex | 5,200 | 19.27 | 100,204 |
| 2021-08-30 | Leonard John M (President and CEO) | Sale | 38,804 | 156.86 | 6,086,679 |
| 2021-08-30 | Leonard John M (President and CEO) | Option Ex | 38,804 | 13.99 | 542,867 |
| 2021-08-23 | Leonard John M (President and CEO) | Sale | 27,139 | 152.71 | 4,144,478 |
| 2021-08-23 | Leonard John M (President and CEO) | Option Ex | 27,139 | 13.40 | 363,662 |
| 2021-08-19 | Leonard John M (President and CEO) | Sale | 22,682 | 151.44 | 3,434,962 |
| 2021-08-19 | Leonard John M (President and CEO) | Option Ex | 22,682 | 13.40 | 303,938 |
| 2021-08-09 | Lebwohl David (EVP, Chief Medical Officer) | Sale | 2,400 | 164.05 | 393,720 |
| 2021-08-09 | Lebwohl David (EVP, Chief Medical Officer) | Option Ex | 2,400 | 12.62 | 30,287 |
| 2021-08-05 | Goddard Glenn (EVP, Chief Financial Officer) | Sale | 20,000 | 151.40 | 3,027,940 |
| 2021-08-05 | Goddard Glenn (EVP, Chief Financial Officer) | Option Ex | 20,000 | 19.27 | 385,400 |
| 2021-08-04 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Sale | 26,000 | 138.71 | 3,606,460 |
| 2021-08-04 | Sepp-lorenzino Laura (EVP, Chief Scientific Officer) | Option Ex | 26,000 | 13.40 | 348,400 |
| 2021-06-28 | Formela Jean Francois | Sale | 553,376 | 135.32 | 74,880,626 |
| 2021-06-14 | Formela Jean Francois | Sale | 170,779 | 87.67 | 14,972,194 |
| 2021-06-11 | Formela Jean Francois | Sale | 30,946 | 85.58 | 2,648,358 |
| 2021-04-29 | Formela Jean Francois | Sale | 4,513 | 85.43 | 385,545 |
| 2021-04-28 | Formela Jean Francois | Sale | 131,926 | 85.76 | 11,313,973 |
| 2021-04-27 | Formela Jean Francois | Sale | 210,230 | 86.29 | 18,141,377 |
| 2021-04-26 | Formela Jean Francois | Sale | 806 | 84.93 | 68,453 |
| 2021-04-13 | Leonard John M (President and CEO) | Option Ex | 25,937 | 10.36 | 268,577 |
| 2021-04-05 | Dorsa Caroline (Director) | Sale | 7,500 | 82.28 | 617,077 |
| 2021-04-05 | Dorsa Caroline (Director) | Option Ex | 7,500 | 6.40 | 48,000 |
| 2021-04-05 | Formela Jean Francois | Sale | 800 | 84.98 | 67,984 |
| 2021-04-01 | Rivera Jose E (EVP, General Counsel) | Sale | 50,455 | 82.98 | 4,186,957 |
| 2021-04-01 | Rivera Jose E (EVP, General Counsel) | Option Ex | 97,001 | 13.40 | 1,299,522 |
| 2021-04-01 | Leonard John M (President and CEO) | Sale | 38,209 | 83.50 | 3,190,451 |
| 2021-04-01 | Leonard John M (President and CEO) | Option Ex | 71,041 | 13.99 | 993,863 |
| 2021-02-26 | Formela Jean Francois | Sale | 501,945 | 60.29 | 30,262,765 |
| 2021-02-09 | Rivera Jose E (EVP, General Counsel) | Sale | 11,489 | 75.00 | 861,675 |
| 2021-02-09 | Rivera Jose E (EVP, General Counsel) | Option Ex | 21,000 | 18.30 | 384,195 |
| 2021-02-09 | Leonard John M (President and CEO) | Sale | 28,043 | 75.00 | 2,103,225 |
| 2021-02-09 | Leonard John M (President and CEO) | Option Ex | 56,718 | 6.83 | 387,383 |
| 2021-02-05 | Leonard John M (President and CEO) | Sale | 22,942 | 67.94 | 1,558,679 |
| 2021-02-05 | Leonard John M (President and CEO) | Option Ex | 40,000 | 13.40 | 536,000 |
| 2021-02-03 | Leonard John M (President and CEO) | Sale | 67,856 | 72.50 | 4,919,560 |
| 2021-02-03 | Leonard John M (President and CEO) | Option Ex | 117,060 | 18.33 | 2,145,709 |
| 2021-02-01 | Rivera Jose E (EVP, General Counsel) | Sale | 54,659 | 64.19 | 3,508,342 |
| 2021-02-01 | Rivera Jose E (EVP, General Counsel) | Option Ex | 109,000 | 11.76 | 1,282,167 |
| 2021-02-01 | Leonard John M (President and CEO) | Sale | 109,889 | 64.14 | 7,048,610 |
| 2021-02-01 | Leonard John M (President and CEO) | Option Ex | 200,000 | 15.45 | 3,089,600 |
| 2021-01-20 | Cohen Fred E (Director) | Option Ex | 20,000 | 13.78 | 275,600 |
| 2021-01-05 | Schiermeier Andrew (EVP, Chief Operating Officer) | Sale | 1,377 | 55.86 | 76,919 |
| 2021-01-05 | Rivera Jose E (EVP, General Counsel) | Sale | 2,078 | 55.86 | 116,077 |
| 2021-01-05 | Leonard John M (President and CEO) | Sale | 6,239 | 55.86 | 348,510 |
| 2020-12-31 | Schiermeier Andrew (EVP, Chief Operating Officer) | Option Ex | 4,792 | .00 | 0 |
| 2020-12-31 | Rivera Jose E (EVP, General Counsel) | Option Ex | 4,792 | .00 | 0 |
| 2020-12-31 | Leonard John M (President and CEO) | Option Ex | 14,375 | .00 | 0 |
| 2020-12-30 | Schiermeier Andrew (EVP, Chief Operating Officer) | Option Ex | 1,500 | 13.48 | 20,220 |
| 2020-12-17 | Karsen Perry A (Director) | Sale | 88,764 | 53.51 | 4,750,027 |
| 2020-12-17 | Karsen Perry A (Director) | Option Ex | 88,764 | 18.53 | 1,644,619 |
| 2020-12-01 | Rivera Jose E (EVP, General Counsel) | Sale | 3,364 | 38.56 | 129,715 |
| 2020-12-01 | Rivera Jose E (EVP, General Counsel) | Option Ex | 5,000 | 13.88 | 69,400 |
| 2020-11-27 | Leonard John M (President and CEO) | Sale | 35,000 | 38.50 | 1,347,500 |
| 2020-11-27 | Leonard John M (President and CEO) | Option Ex | 35,000 | 16.44 | 575,400 |
| 2020-11-25 | Leonard John M (President and CEO) | Sale | 50,000 | 36.00 | 1,800,000 |
| 2020-11-25 | Leonard John M (President and CEO) | Option Ex | 50,000 | 6.83 | 341,500 |
| 2020-11-18 | Rivera Jose E (EVP, General Counsel) | Sale | 624 | 35.00 | 21,840 |
| 2020-11-18 | Rivera Jose E (EVP, General Counsel) | Option Ex | 848 | 18.30 | 15,518 |
| 2020-11-16 | Rivera Jose E (EVP, General Counsel) | Sale | 6,029 | 34.42 | 207,518 |
| 2020-11-16 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,562 | 12.56 | 132,711 |
| 2020-11-16 | Leonard John M (President and CEO) | Sale | 20,000 | 34.00 | 680,000 |
| 2020-11-16 | Leonard John M (President and CEO) | Option Ex | 20,000 | 14.58 | 291,600 |
| 2020-11-04 | Rivera Jose E (EVP, General Counsel) | Sale | 3,364 | 28.00 | 94,192 |
| 2020-11-04 | Rivera Jose E (EVP, General Counsel) | Option Ex | 5,000 | 13.88 | 69,400 |
| 2020-11-04 | Leonard John M (President and CEO) | Sale | 50,000 | 26.00 | 1,300,000 |
| 2020-11-04 | Leonard John M (President and CEO) | Option Ex | 50,000 | 6.83 | 341,500 |
| 2020-10-15 | Rivera Jose E (EVP, General Counsel) | Sale | 5,615 | 24.37 | 136,837 |
| 2020-10-15 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,000 | 6.83 | 68,300 |
| 2020-10-07 | Leonard John M (President and CEO) | Sale | 5,000 | 21.83 | 109,149 |
| 2020-10-07 | Leonard John M (President and CEO) | Option Ex | 5,000 | 6.83 | 34,150 |
| 2020-09-15 | Rivera Jose E (EVP, General Counsel) | Sale | 5,615 | 21.04 | 118,139 |
| 2020-09-15 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,000 | 6.83 | 68,300 |
| 2020-09-01 | Leonard John M. (President and CEO) | Sale | 5,000 | 21.83 | 109,149 |
| 2020-09-01 | Leonard John M. (President and CEO) | Option Ex | 5,000 | 6.83 | 34,150 |
| 2020-08-18 | Rivera Jose E (EVP, General Counsel) | Sale | 5,615 | 21.00 | 117,915 |
| 2020-08-18 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,000 | 6.83 | 68,300 |
| 2020-08-06 | Leonard John M. (President and CEO) | Sale | 5,000 | 21.83 | 109,149 |
| 2020-08-06 | Leonard John M. (President and CEO) | Option Ex | 5,000 | 6.83 | 34,150 |
| 2020-07-15 | Rivera Jose E (EVP, General Counsel) | Sale | 5,615 | 22.70 | 127,460 |
| 2020-07-15 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,000 | 6.83 | 68,300 |
| 2020-07-01 | Leonard John M. (President and CEO) | Sale | 5,000 | 21.83 | 109,149 |
| 2020-07-01 | Leonard John M. (President and CEO) | Option Ex | 5,000 | 6.83 | 34,150 |
| 2020-06-16 | Rivera Jose E (EVP, General Counsel) | Sale | 5,615 | 21.00 | 117,915 |
| 2020-06-16 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,000 | 6.83 | 68,300 |
| 2020-06-03 | Leonard John M. (President and CEO) | Sale | 5,000 | 21.83 | 109,149 |
| 2020-06-03 | Leonard John M. (President and CEO) | Option Ex | 5,000 | 6.83 | 34,150 |
| 2020-05-26 | Rivera Jose E (EVP, General Counsel) | Sale | 5,615 | 21.21 | 119,094 |
| 2020-05-26 | Rivera Jose E (EVP, General Counsel) | Option Ex | 10,000 | 6.83 | 68,300 |
| 2019-03-06 | Schiermeier Andrew (EVP, Dev and Corp Strategy) | Buy | 7,500 | 15.75 | 118,125 |
| 2018-07-16 | Formela Jean Francois (Director) | Sale | 6,686 | 31.45 | 210,261 |
| 2018-06-19 | Formela Jean Francois (Director) | Sale | 6,686 | 28.11 | 187,976 |
| 2018-05-16 | Formela Jean Francois (Director) | Sale | 6,686 | 25.04 | 167,390 |
| 2018-05-14 | Leonard John M. (President and CEO) | Sale | 8,400 | 24.00 | 201,600 |
| 2018-03-28 | Bell Graeme (EVP, Chief Financial Officer) | Option Ex | 8,000 | 13.48 | 107,840 |
| 2018-03-20 | Formela Jean Francois (Director) | Sale | 39,245 | 24.42 | 958,441 |
| 2018-01-29 | Caribou Biosciences, Inc. | Sale | 550,645 | 26.78 | 14,746,273 |
| 2017-12-12 | Novartis Ag (10% Owner) | Sale | 1,523,000 | 18.30 | 27,870,900 |
| 2017-12-08 | Bermingham Nessan (President & CEO) | Sale | 94,143 | 20.82 | 1,960,151 |
| 2017-12-07 | Bermingham Nessan (President & CEO) | Sale | 131,140 | 21.25 | 2,787,249 |
| 2017-12-06 | Bermingham Nessan (President & CEO) | Sale | 111,500 | 20.56 | 2,292,328 |
| 2017-09-13 | Caribou Biosciences, Inc. | Sale | 1,048,846 | .00 | 0 |
| 2017-07-11 | Atlas Venture Associates Ix, Llc (10% Owner) | Sale | 80,000 | 16.07 | 1,285,600 |
| 2017-07-11 | Formela Jean Francois (Director) | Sale | 80,000 | 16.07 | 1,285,600 |
| 2017-07-10 | Atlas Venture Associates Ix, Llc (10% Owner) | Sale | 40,000 | 16.17 | 646,880 |
| 2017-07-10 | Formela Jean Francois (Director) | Sale | 40,000 | 16.17 | 646,880 |
| 2017-07-07 | Atlas Venture Associates Ix, Llc (10% Owner) | Sale | 30,000 | 16.77 | 502,979 |
| 2017-07-07 | Formela Jean Francois (Director) | Sale | 30,000 | 16.77 | 502,979 |
| 2017-03-10 | Atlas Venture Associates Ix, Llc (10% Owner) | Sale | 5,504 | 14.06 | 77,408 |
| 2017-03-10 | Formela Jean Francois (Director) | Sale | 5,504 | 14.06 | 77,408 |
| 2017-03-09 | Atlas Venture Associates Ix, Llc (10% Owner) | Sale | 15,628 | 13.85 | 216,432 |
| 2017-03-09 | Formela Jean Francois (Director) | Sale | 15,628 | 13.85 | 216,432 |
| 2016-05-11 | Tls Beta Pte. Ltd. (10% Owner) | Buy | 300,000 | 18.00 | 5,400,000 |
| 2016-05-11 | Baker Bros. Advisors (gp) Llc (Other) | Buy | 200,000 | 18.00 | 3,600,000 |
| 2016-05-11 | Gordon Carl L (Director) | Buy | 250,000 | 18.00 | 4,500,000 |
| 2016-05-11 | Novartis Ag (10% Owner) | Buy | 277,777 | 18.00 | 4,999,986 |
| 2016-05-11 | Isaly Samuel D (Director) | Buy | 250,000 | 18.00 | 4,500,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of NTLA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Intellia Therapeutics, Inc. (symbol NTLA, CIK number 1652130) see the Securities and Exchange Commission (SEC) website.